Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
HOME > COMMENTARY
COMMENTARY
-
Challenges Emerging from Hiroshima: Improvement of Wholesalers' “Services of Convenience”
August 1, 2012
-
Integration of Advanced Healthcare System to Strengthen Linkage Between Development, Insurance, and Regulatory Approval
July 10, 2012
-
Major Generic Drug Makers Trying New Strategies to Boost Product Strengths
July 6, 2012
-
Gov’t to Support Development of Innovative Drugs of Japanese Origin through Drug Discovery Support Network
June 22, 2012
-
Discussions on Long-Listed Drugs Must Balance Interests of All Stakeholders
June 14, 2012
-
Supply of New Drugs Prior to NHI Price Listing to Increase as More Makers Target Drugs with Unmet Medical Needs
April 20, 2012
-
Fewer Takers, High Pass Rate in Nat’l Pharmacists’ Exam for 1st Graduates of Six-year Education System
April 5, 2012
-
Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 2
March 26, 2012
-
Recent Topics in Hopeful Drugs and Candidates with Unique Mode of Action: 1
March 19, 2012
-
Indications for Boosted Alliances, Acquisitions in Vaccine Business among Major Japanese Companies
March 13, 2012
-
Further Provisions Required – One Year since the Great East Japan Earthquake
March 12, 2012
-
Major US, European Drug Makers Report Growth in 2011 as Patent Cliff Approaches
March 5, 2012
-
Will Wholesalers Be Able to Succeed at Reform This Time?
February 20, 2012
-
Industry Should Prepare Arguments in Advance to Ward Off Possibility of 3 Consecutive NHI Price Revisions
January 23, 2012
-
Will New Drug Makers Dominate Domestic Biosimilars Market?
December 26, 2011
-
Pressure Mounting for Additional NHI Price Cut for Long-listed Drugs
December 12, 2011
-
“Drug Discovery Support Organization” Faces Doubts: Can It Pick Winners?
November 28, 2011
-
Perpetuation of Premium for New Drug Development Faces Hurdles
November 14, 2011
-
Further Research Needed to Advance the Use of Regulatory Science in Regulatory Affairs
November 14, 2011
-
Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
October 19, 2011
ページ
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…